Clinical and Translational Medicine

Table 3 Multivariate analysis for progression free survival in our cohort

From: EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Characteristics	Multivariate analyses
Characteristics	HR (95% CI)	P value
Model 1
TP53 status
Mutated	1.00 (Reference)
Wild type	0.66 (0.31–1.43)	0.298
T790M RMA (continuous)	1.14 (0.49–2.66)	0.766
T790M RMP (continuous)	0.15 (0.03–0.79)	0.025
Model 2
TP53 status
Mutated	1.00 (Reference)
Wild type	0.58 (0.28–1.24)	0.161
T790M RMA (categorical)
≤ 0.30	1.00 (Reference)
> 0.30	0.71 (0.31–1.61)	0.409
T790M RMP (categorical)
≤ 0.24	1.00 (Reference)
> 0.24	0.46 (0.20–1.05)	0.066

HR hazard ratio, CI confidence interval, RMA Relative mutation abundance, RMP Relative mutation purity

Back to article page